Marc Spielmann
Institut Gustave Roussy
121 Papers
1.9K Citations
Marc Spielmann is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 46, co-authored 121 publications. Previous affiliations of Marc Spielmann include Université Paris-Saclay & University of Texas MD Anderson Cancer Center.
Chat about Author
Papers
Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial
Henri Roché,Pierre Fumoleau,Marc Spielmann,Jean-Luc Canon,Thierry Delozier,D. Serin,Michel Symann,Pierre Kerbrat,Patrick Soulié,Françoise Eichler,Patrice Viens,A. Monnier,A. Vindevoghel,Mario Campone,Marie-Josèphe Goudier,Jacques Bonneterre,Jean-Marc Ferrero,Anne-Laure Martin,Jean Genève,Bernard Asselain +19 more
TL;DR: The PACS 01 trial as mentioned in this paper compared six cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC) with a sequential regimen of three cycles of FEC followed by three cycle of docetaxel as adjuvant treatment for node-positive early breast cancer.
601
Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer.
Danièle Sarrazin,M. G. Lê,Rodrigo Arriagada,Geneviève Contesso,F. Fontaine,Marc Spielmann,F. Rochard,Th. Le Chevalier,Jean Lacour +8 more
TL;DR: A randomized trial was conducted at the Institut Gustave-Roussy between 1972 and 1980 comparing tumorectomy and breast irradiation with modifiedradical mastectomy with modified radical mastectomy, with no significant differences between the two treatment groups.
580
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: The FNCLCC PACS 01 trial
Henri Roché,Pierre Fumoleau,Marc Spielmann,Jean-Luc Canon,Thierry Delozier,D. Serin,Michel Symann,Pierre Kerbrat,Patrick Soulié,Françoise Eichler,Patrice Viens,A. Monnier,A. Vindevoghel,Mario Campone,Marie-Josèphe Goudier,Jacques Bonneterre,Jean-Marc Ferrero,Anne-Laure Martin,Jean Genève,Bernard Asselain +19 more
- 01 Jan 2006
TL;DR: Sequential adjuvant chemotherapy with FEC followed by docetaxel significantly improves disease-free and overall survival in node-positive breast cancer patients and has a favorable safety profile.
377
Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review
Elisabeth Luporsi,Fabrice Andre,Frédérique Spyratos,Pierre-Marie Martin,Jocelyne Jacquemier,Frédérique Penault-Llorca,Nicole Tubiana-Mathieu,Brigitte Sigal-Zafrani,Laurent Arnould,Anne Gompel,Caroline Egele,Bruno Poulet,Krishna B. Clough,Hubert Crouet,Alain Fourquet,Jean-Pierre Lefranc,Carole Mathelin,Nicolas Rouyer,Daniel Serin,Marc Spielmann,Margaret Haugh,Marie-Pierre Chenard,Etienne Brain,Patricia de Cremoux,Jean-Pierre Bellocq +24 more
TL;DR: KI-67 is an independent prognostic factor for disease-free survival in multivariate analyses studies using samples from randomized clinical trials with secondary central analysis of the biomarker, and its prognostic and predictive value is focused on.
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials
Rosie Bradley,Jeremy P Braybrooke,Richard Gray,Robert Kerrin Hills,Z Liu,Richard Peto,Lucy Davies,David Dodwell,Paul McGale,Hongchao Pan,Carolyn W. Taylor,Stewart J. Anderson,Richard D. Gelber,Luca Gianni,William Jacot,Heikki Joensuu,Alvaro Moreno-Aspitia,Martine Piccart,Michael F. Press,Edward Romond,Dennis J. Slamon,Vera J. Suman,Richard Berry,Clare Boddington,Mike Clarke,C Davies,Fran Duane,Vaughan Evans,Lucy Gettins,Jon Godwin,Sam James,Hui Liu,Elizabeth MacKinnon,Gurdeep S. Mannu,Theresa McHugh,Philip Morris,Simon Read,Ewan Straiton,Yaochen Wang,John Crown,Evandro de Azambuja,Suzette Delaloge,Helena Fung,Charles E. Geyer,Marc Spielmann,Pinuccia Valagussa,Kathy S. Albain,Rodrigo Arriagada,John D. Bartlett,Elizabeth Bergsten-Nordström,Judith M Bliss,Etienne Brain,Lisa A. Carey,Robert E. Coleman,Jack Cuzick,Nancy E. Davidson,Lucia Del Mastro,Angelo Di Leo,James J. Dignam,Mitch Dowsett,Bent Ejlertsen,Prue Francis,Michael Gnant,Matthew Bidwell Goetz,Pam Goodwin,Pat Halpin-Murphy,Daniel F. Hayes,Christopher Hill,Reshma Jagsi,Wolfgang Janni,Sibylle Loibl,Eleftherios P. Mamounas,Miguel Martín,Hirofumi Mukai,Valentina Nekljudova,Larry Norton,Yasuo Ohashi,Lori J. Pierce,Philip Poortmans,Vinod Raina,Daniel Rea,Meredith M. Regan,John F.R. Robertson,Emiel J. Th. Rutgers,Tanja Spanic,Joseph A. Sparano,Guenther G. Steger,Gong Tang,Masakazu Toi,Andrew Tutt,Giuseppe Viale,Xiang Wang,Timothy J. Whelan,Nicholas Wilcken,Norman Wolmark,David Cameron,Jonas Bergh,Kathleen I. Pritchard,Sandra M. Swain +98 more
TL;DR: In this paper, the authors investigated the long-term benefits and risks of adjuvant trastuzumab on breast cancer recurrence and cause-specific mortality, and did a collaborative meta-analysis of individual patient data from randomised trials.
231